New drug duo aims to control Tough-to-Treat breast cancer
NCT ID NCT05230810
Summary
This study is testing whether combining two targeted drugs, tucatinib and alpelisib, can help control advanced HER2-positive breast cancer that has a specific genetic change (PIK3CA mutation). The first part checks the safety and best dose of the combination. The second part expands to see how well it works at stopping cancer growth in about 40 patients who have already tried other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Care & Hematology-Fort Collins
Fort Collins, Colorado, 80528, United States
-
Louisiana State University Health Sciences Center
New Orleans, Louisiana, 70112, United States
-
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.